• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Cartesian Therapeutics Inc.

    7/17/24 11:45:01 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNAC alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001453687
    SELECTA BIOSCIENCES INC
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Cartesian Therapeutics, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Cartesian Therapeutics, Inc.
    Street Address 1 Street Address 2
    704 QUINCE ORCHARD RD
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    GAITHERSBURG MARYLAND 20878 617-923-1400

    3. Related Persons

    Last Name First Name Middle Name
    Brunn Carsten
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Davis Blaine
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cox Carrie S.
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Barabe Timothy C.
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    de Silva Nishan
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kalayoglu Murat
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Malik Kemal
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Singer Michael
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Springer Timothy A.
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Zenner Patrick
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kurtoglu Metin
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Miljkovic Milos
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Jewell Chris
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    English Emily
    Street Address 1 Street Address 2
    704 Quince Orchard Road
    City State/Province/Country ZIP/PostalCode
    Gaithersburg MARYLAND 20878
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-07-02    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    common stock and convertible preferred stock convertible into common stock

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $130,023,000 USD
    or    Indefinite
    Total Amount Sold $130,023,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    22

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $4,969,980 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Cartesian Therapeutics, Inc. /s/ Blaine Davis Blaine Davis Chief Financial Officer 2024-07-17

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $RNAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNAC

    DatePrice TargetRatingAnalyst
    7/9/2025$38.00Outperform
    Wedbush
    12/19/2024$42.00Buy
    BTIG Research
    8/6/2024Buy
    TD Cowen
    7/2/2024Outperform → Perform
    Oppenheimer
    6/4/2024$50.00Outperform
    Oppenheimer
    5/24/2024$40.00Buy
    Mizuho
    4/23/2024$2.00 → $54.00Buy
    H.C. Wainwright
    4/23/2024$39.00Outperform
    Leerink Partners
    More analyst ratings

    $RNAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Brunn Carsten sold $162,077 worth of shares (23,766 units at $6.82), decreasing direct ownership by 7% to 323,530 units (SEC Form 4)

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    1/8/26 4:20:02 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Davis Blaine sold $72,227 worth of Common Stock (10,591 units at $6.82), decreasing direct ownership by 8% to 121,220 units (SEC Form 4)

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    1/8/26 4:19:50 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Miljkovic Milos sold $24,367 worth of Common Stock (3,573 units at $6.82), decreasing direct ownership by 6% to 58,820 units (SEC Form 4)

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    1/8/26 4:19:56 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cartesian Therapeutics Inc.

    SCHEDULE 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

    2/5/26 1:20:38 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

    1/9/26 8:06:08 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

    12/18/25 4:13:02 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barabe Timothy C bought $205,797 worth of shares (30,000 units at $6.86), increasing direct ownership by 123% to 54,366 units (SEC Form 4)

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    12/8/25 4:07:12 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Springer Timothy A bought $1,522,517 worth of shares (149,075 units at $10.21), increasing direct ownership by 0.26% to 8,643,685 units (SEC Form 4)

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    4/11/25 5:29:40 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Springer Timothy A bought $1,371,154 worth of shares (89,863 units at $15.26), increasing direct ownership by 1% to 8,621,325 units (SEC Form 4)

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    3/20/25 7:50:25 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $RNAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cartesian Therapeutics Announces New Employment Inducement Grants

    FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company's common stock with an exercise price of $6.79, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Compa

    2/3/26 7:05:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

    Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune dise

    1/9/26 8:04:14 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics Announces New Employment Inducement Grants

    FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company's common stock with an exercise price of $6.76, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company

    1/6/26 7:05:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Cartesian Therapeutics with a new price target

    Wedbush initiated coverage of Cartesian Therapeutics with a rating of Outperform and set a new price target of $38.00

    7/9/25 8:26:19 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Cartesian Therapeutics with a new price target

    BTIG Research initiated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $42.00

    12/19/24 8:25:53 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Cartesian Therapeutics

    TD Cowen initiated coverage of Cartesian Therapeutics with a rating of Buy

    8/6/24 6:25:49 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAC
    Financials

    Live finance-specific insights

    View All

    Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

    Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo Deepening responses observed over time in Phase 2b trial, with Descartes-08-treated participants observed to have a 5.5-point reduction in MG-ADL at Month 4 Durable responses observed through Month 12 in Phase 2b trial Safety profile consistent with previously reported data and continues to support outpatient administration Company to host conference call and webcast with key opinion leader today at 7:30 a.m. ET FREDERICK, Md., Dec. 03, 2024 (GLOB

    12/3/24 6:00:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

    FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis will be presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, being held December 2-4, 2024 in Philadelphia. Details of the presentation are as follows: Title: Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to ClinicSession Name: Diving into Challenges & Successes in the Autoimmune Space to Direct Futu

    11/21/24 7:00:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

    Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up to at least six months observed in patients treated with Descartes-08 Safety profile continues to support outpatient administration Company expects to hold End-of-Phase 2 meeting with the FDA by year-end Company to host conference call today at 8:00 a.m. ET GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneerin

    7/2/24 6:30:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAC
    Leadership Updates

    Live Leadership Updates

    View All

    Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

    Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune dise

    1/9/26 8:04:14 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

    FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company's Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science and Technology Committee of the Board. "Dr. Bot brings a unique perspective shaped by pioneering work in first-in-class CAR T cell therapies, including the recent historic acquisition of Capstan's no

    12/18/25 4:05:00 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

    Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $220.9M of cash, cash equivalents, and restricted cash as of September 30, 2024 expected to support planned operations, including completion of planned Phase

    11/7/24 7:00:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

    SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

    11/18/24 9:44:37 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

    SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

    10/15/24 4:30:56 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

    SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

    10/4/24 6:08:15 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care